EXTON, Pa.--(BUSINESS WIRE)--Morphotek®, Inc., a subsidiary of Eisai Corporation of North America, today announced the signing of an evaluation agreement with the University Hospital Heidelberg and its Technology Transfer Office, Germany to advance the company's efforts in the discovery and development of therapeutic antibodies in oncology. The agreement provides for a research grant to the University Hospital/National Center for Tumor Diseases (NCT) and for use by Morphotek of biological materials to generate and validate therapeutic monoclonal antibodies to oncology targets selected by Morphotek.
